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Outcomes and practice patterns in patients
undergoing lower extremity bypass
Jessica P. Simons, MD, MPH,a Andres Schanzer, MD,a Brian W. Nolan, MD, MS,b
David H. Stone, MD,b Jeffrey A. Kalish, MD,c Jack L. Cronenwett, MD,b and
Philip P. Goodney, MD, MS,b on behalf of the Vascular Study Group of New England, Worcester and
Boston, Mass; and Lebanon and Hanover, NH
Background: The appropriate application of endovascular intervention vs bypass for both critical limb ischemia (CLI) and
intermittent claudication (IC) remains controversial, and outcomes from large, contemporary series are critical to help
inform treatment decisions. Therefore, we sought to define the early and 1-year outcomes of lower extremity bypass
(LEB) in a large, multicenter regional cohort, and analyze trends in the use of LEB with or without prior endovascular
interventions.
Methods: The Vascular Study Group of New England database was used to identify all infrainguinal LEB procedures
performed between 2003 and 2009. The primary study endpoint was 1-year amputation-free survival (AFS). Secondary
endpoints included in-hospital mortality and morbidity, including major adverse cardiac events. Trend analyses were
conducted to identify annual trends in the proportion of LEBs performed for an indication of IC, in-hospital outcomes,
including mortality and morbidity, and 1-year outcomes, including AFS. Analyses were performed on the entire cohort
and then stratified by indication.
Results: Between 2003 and 2009, 2907 patients were identified who underwent LEBs (72% for CLI; 28% for IC). The
proportion that underwent LEB for IC increased significantly over the study period (from 19% to 31%; P< .0001). There
was a significant increase over time in the proportion of LEBs performed after a previous endovascular intervention
among both CLIs (from 11% to 24%; P < .0001) and ICs (from 13% to 23%; P  .02). Neither in-hospital mortality nor
cardiac event rates changed significantly among either group. There was no significant change in 1-year AFS in patients with
IC (97% in 2003 and 98% in 2008; P for trend .63) or in patients with CLI (73% in 2003 and 81% in 2008; P  .10).
Conclusions: Over the last 7 years, significant changes in patient selection for LEBs have occurred in New England. The
proportion of LEBs performed for ICs as opposed to CLIs has increased. Patients are muchmore likely to have undergone
prior endovascular interventions before undergoing a bypass. In-hospital and 1-year outcomes after LEB for both IC and
CLI have remained excellent with no significant changes in AFS. (J Vasc Surg 2012;55:1629-36.)
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wManagement of chronic lower extremity ischemia is
complex. The severity of symptoms varies widely, from
mild claudication to extensive tissue loss. Revascularization
strategies differ significantly, with both traditional open
approaches and newer endovascular therapies available.
Decision-making centers around selecting those patients
who require intervention and choosing the type of inter-
vention that will prove most beneficial over the individual
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doi:10.1016/j.jvs.2011.12.043atient’s anticipated life-span. In order to weigh the risks
nd benefits of intervention, contemporary estimates of the
orbidity and mortality associated with a given procedure
re critical.
Much of the current fund of knowledge on outcomes
ssociated with lower extremity bypass (LEB) is derived
rom highly selected populations of patients studied within
andomized trials, or from large series accumulated at
ingle centers of excellence. For example, while the Pro-
ect or Ex-Vivo vein graft Engineering via Transfection
PREVENT) III1 and Bypass Versus Angioplasty in Severe
schaemia of the Leg (BASIL)2 cohorts have proved invalu-
ble in studying the efficacy of competing treatment op-
ions for critical limb ischemia (CLI), the patients and
esults obtained in these settings may not accurately reflect
eal-world practice. Further, while single-institution se-
ies3,4 may provide insight into a local surgical practice,
hese studies may not be broadly generalizable.
In order to define contemporary practice patterns in the
eal-world management of patients with lower extremity
eripheral arterial disease, we analyzed a prospectively col-
ected regional database of patients who underwent LEB
or chronic lower extremity ischemia. We evaluated in-
ospital and 1-year outcomes, looking separately at patients
ith intermittent claudication (IC) and those with CLI.
e sought to characterize temporal changes in the utiliza-
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June 20121630 Simons et altion and the outcomes associated with LEB, focusing on
amputation-free survival (AFS), graft patency, and in-
hospital morbidity.
METHODS
Cohort assembly. Data were obtained from the pro-
spectively collected Vascular Study Group of New England
(VSGNE) registry. The VSGNE is a regional cooperative
quality improvement initiative that was developed in 2002
to prospectively evaluate outcomes in patients undergoing
vascular surgery. By the end of the period of study, there
were a total of 12 teaching and nonteaching hospitals with
52 vascular surgeons (community and academic) who par-
ticipated in this program by reporting data into the registry.
There were seven centers participating in 2003. The dataset
used for this analysis did not exclude any of these surgeons
or centers; it was not abstracted from any subset. All data
are self-reported and sent to a central data repository where
they are aggregated and reviewed. Research analysts are
blinded to patient, surgeon, and hospital identity.
At the time of discharge after the index operation,
in-hospital data comprising preoperative, intraoperative,
and postoperative data are completed and submitted to the
VSGNE. The study design for the VSGNE registry man-
dates the collection of follow-up data at 1 year for all
patients with procedures entered into the registry. To facil-
itate compliance with this requirement, the web-based
system generates follow-up forms for each operation in
advance of the expected 1-year office visit. Data pertain-
ing to ambulation status, symptom status, patency, ankle-
brachial index, bypass graft revisions, or amputations are
recorded on this form. Since the inception of the study, a
claims-based audit system has been used that has demon-
strated 99% accuracy in capturing consecutive operations
performed at each center. Details relating to the VSGNE
study design have been published previously5 and are avail-
able at the VSGNEwebsite (http://www.VSGNE.org). In
brief, the VSGNE takes several measures to ensure the
accuracy of data entry, including holding biannual meet-
ings for all surgeons and research assistants. They also
correlate submitted results from each hospital with hospital
claims, which ensures accurate case reporting and validates
hospital discharge status. Detailed definitions have been
provided to data abstractors alongwith newsletters address-
ing specifics of data entry. The central data collection site is
also available to answer questions concerning data abstrac-
tion.
For the purpose of this study, the VSGNE database was
queried to identify patients undergoing elective and urgent
infrainguinal LEB performed between January 1, 2003,
and December 31, 2009, for an indication of CLI (defined
as tissue loss or ischemic rest pain) or IC; patients with
acute limb ischemia and those undergoing LEB for aneu-
rysmal disease were not included. Those without an indica-
tion specified were excluded (n 382). The urgency of the
procedure was determined by the surgeon as elective, ur-
gent, or emergent. All infrainguinal bypass configurations
were included for analysis, regardless of the specific inflow pite, outflow site, or conduit. For all analyses of 1-year
utcomes, data from patients who underwent LEB in 2009
ere excluded because 1-year follow-up data were not yet
vailable.
Covariates examined. Patient information for 100
linical and demographic variables (available at http://
ww.VSGNE.org) was collected. Preoperative variables
xamined included the year the procedure was performed,
s well as indication for LEB, defined as either IC or CLI.
reoperative use of cardioprotective medications was de-
ned as antiplatelet agents, statins, or beta blockers. Both
he individual medication types were investigated as well as
composite variable, any cardioprotective medication.
rior endovascular intervention, either suprainguinal or
nfrainguinal, on the ipsilateral limb was also evaluated.
ther variables collected included comorbidities such as
oronary artery disease (CAD; history of myocardial infarc-
ion [MI], or angina), chronic obstructive pulmonary dis-
ase (medication-dependent or home oxygen-dependent),
ongestive heart failure (by history), diabetes mellitus (in-
ulin-dependent or controlled by oral medication or diet),
ypertension (history of hypertension or blood pressure
140/90 mm Hg on the preoperative evaluation), and
istory of tobacco use (never, 1 year prior, or current).
ariables related to surgical history included previous cor-
nary artery bypass graft or percutaneous coronary inter-
ention, as well as previous carotid or aortic procedure, and
ajor extremity amputation (defined as above- or below-
nee amputation).
One-year follow-up data included mortality, graft pa-
ency (primary, primary-assisted, or secondary, determined
y either angiography or duplex graft surveillance scan),
nd major amputation (above- or below-knee). Vital status
as confirmed for all patients using follow-up visit notes
nd a recent version of the Social Security Death Index.
Main outcome measures. The primary endpoint was
FS, a composite endpoint defined as freedom from ipsi-
ateral major amputation and freedom from all-cause mor-
ality at 1-year follow-up. Graft patency at 1-year follow-up
as also ascertained. Secondary endpoints included in-
ospital mortality, wound infection, cardiac complications,
nd need for reoperation. Cardiac complications were de-
ned as a composite of either MI (defined as either tro-
onin elevation, changes on electrocardiogram, or clinically
iagnosed) or new dysrhythmia during the index hospital-
zation. Need for reoperation was defined as return to the
perating room within the index admission for infection,
hrombosis, or revision. Length of hospital stay was also
scertained. Trend analyses were conducted to assess for
ime-dependent changes in these outcomes over the study
eriod.
Statistical analysis. Descriptive statistics were used to
dentify the proportion of bypasses performed on an annual
asis for IC compared to CLI. There were 7 hospitals that
ontributed data in 2003; this increased to 12 hospitals by
009. In order to assess whether the addition of new sites
o the database on an annual basis had an effect on the
roportion of LEBs performed for ICs, annual comparisons
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indication for LEB) in the existing centers and that among
the new centers added that same year. Of note, the years of
study were divided into 5 time periods in order to maintain
anonymity of the individual sites as they were added. Com-
parisons were made between time periods. Categorical
variables were compared using Pearson 2 analysis. Coch-
ran Armitage tests of trend were used to evaluate for trends
over the study period. Analyses were performed on the
entire cohort as well as on each subgroup after stratification
by indication for LEB (IC and CLI). For 1-year outcomes,
Kaplan-Meier analysis was used to assess graft patency,
overall survival, and AFS. Intergroup comparisons were
made using log-rank tests. Tests of trend for 1-year end-
points were conducted by linear regression using the 1-year
estimates, and assessing the goodness of fit. Significance
was accepted at the P  .05 level. All analyses were con-
ducted using SAS, version 9.2, software (SAS Institute,
Table I. Demographics of patients who underwent infrain
New England from 2003 to 2009, with univariate analysis
Covariates
Total
n  2907
Demographics No. (%)
Age (mean  SD in years) 68.3 (11.4)
Gender (female) 902 (31.0)
Race
White 2859 (99.2)
Nonwhite 22 (0.8)
Year of procedure
2003 397 (13.6)
2004 385 (13.2)
2005 383 (13.2)
2006 380 (13.1)
2007 422 (14.5)
2008 463 (15.9)
2009 477 (16.4)
Preoperative factors
Smoking status
Never smoker 469 (16.2)
History of smoking 1310 (45.1)
Current smoker 1123 (38.7)
CAD 1106 (38.1)
History of CABG or PCI 970 (33.4)
CHF 494 (17)
Hypertension 2517 (86.6)
Insulin-dependent diabetes 761 (26.2)
COPD 853 (29.4)
Prosthetic conduit 799 (27.5)
Previous surgery
Endovascular intervention (ipsi) 545 (18.8)
Aortic surgery 112 (3.9)
Carotid surgery 311 (10.7)
Arterial bypass (any) 918 (31.6)
Major amputation (contra) 112 (3.9)
Cardioprotective medications
Aspirin 2093 (72.1)
Clopidogrel 295 (10.2)
Statin 1837 (63.3)
Beta blocker 2378 (82.3)
CABG, Coronary artery bypass graft; CAD, coronary artery disease; CHF, c
chronic obstructive pulmonary disease; IC, intermittent claudication; ipsi, ipCary, NC). 3ESULTS
Patient characteristics. A total of 3289 LEBs, per-
ormed on 2850 patients, were identified between 2003
nd 2009 in the VSGNE database. Of these, 797 (27%)
ere performed for IC and 2110 (73%) were performed for
LI (indication was missing in 382). The mean age was
8.3 years and 902 LEBs (31%) were performed on women
Table I). Previous ipsilateral bypass had been performed in
81 patients (13.1%). Patients undergoing LEB for CLI as
ompared with IC had more comorbid conditions, including
AD, congestive heart failure, insulin-dependent diabetes,
nd hypertension (Table I). Cardioprotective medications
ere applied differently, with the IC group being significantly
ore likely to receive aspirin and statins, while the CLI group
as more likely to receive beta blockers. There was no signif-
cant difference in the rates of previous endovascular interven-
ion between groups, with 150 (18.8%) in the IC group, and
al lower extremity bypass in the Vascular Study Group of
dication
IC
 797 (27.4%)
CLI
n  2110 (72.6%) P value
No. (%) No. (%)
64.3 (10.4) 69.9 (11.4) .0001
205 (25.7) 697 (33.0) .0001
.06
783 (98.7) 2076 (99.4)
10 (1.3) 12 (0.6)
.0001
76 (9.5) 321 (15.2)
81 (10.1) 304 (14.4)
117 (14.7) 266 (12.6)
99 (12.4) 281 (13.3)
140 (17.6) 282 (13.4)
137 (17.2) 326 (15.5)
147 (18.4) 330 (15.6)
.0001
82 (10.3) 387 (18.4)
344 (43.3) 966 (45.9)
369 (46.4) 754 (35.8)
244 (30.7) 862 (40.9) .0001
256 (32.1) 714 (33.9)
46 (5.8) 448 (21.2) .0001
647 (81.2) 1870 (88.6) .0001
91 (11.4) 670 (31.8) .0001
217 (21.3) 636 (30.2) .13
278 (34.9) 521 (24.7) .0001
150 (18.8) 395 (18.7) .95
37 (4.6) 75 (3.6) .17
96 (12.1) 215 (10.2) .15
239 (30.0) 679 (32.2) .25
7 (0.9) 105 (5.0) .0001
602 (75.7) 1491 (70.8) .0079
69 (8.7) 226 (10.7) .10
561 (70.5) 1276 (60.6) .0001
609 (77.1) 1769 (84.3) .0001
tive heart failure; CLI, critical limb ischemia; contra, contralateral; COPD,
ral; PCI, percutaneous coronary intervention.guin
by in
n
onges95 (18.7%) in the CLI group (P .95).
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were more common among the CLI group. While in-
hospital mortality for the total cohort was 1.6%, in-hospital
mortality was sevenfold higher in the CLI group (2.1% vs
0.3%; P  .0003). Rates of wound infection, need for
reoperation, in-hospital MI or dysrhythmia, and mean
lengths of stay were all significantly higher in the CLI group
(Table II).
Outcomes at 1-year follow-up. Mean long-term fol-
low up was 331 days. One-year outcomes were more favor-
able in the IC group (Table II). One-year mortality for the
total cohort was 11% (IC 4% vs CLI 14%; P  .0001).
Patients with IC experienced a lower rate of major ampu-
tation at 1 year than patients with CLI (2% vs 12%; P 
.0001). Graft patency was also significantly better in the IC
group when compared to the CLI group (IC: primary 79%,
primary-assisted 87%, secondary 89%; CLI: primary 66%,
primary-assisted 75%, secondary 77%). Survival data was
missing for 7% of cases. When stratified by history of
endovascular intervention, AFS among IC met statistical
significance (log-rank, P  .05); however, it should be
noted that there were no events in the prior endovascular
intervention group by 1 year. There was no significant
difference in AFS among the CLI group when stratified by
history of endovascular intervention (log-rank, P  .14).
Time trends in patient characteristics by indication.
Among the total cohort, there was a steady increase in the
use of any cardioprotective medication, increasing from
92% in 2003 to 98% in 2009 (P  .0001). This trend was
observed in both the IC group (90% in 2003 and 97% in
2009; P  .009), and in the CLI group (93% in 2003 and
98% in 2009; P .0001). Utilization of specific cardiopro-
tective medications reveals a significant increase in the use
of aspirin (P .0001), clopidogrel (P .0001), statins (P
.006), and beta blockers (P  .028) among claudicants
(Fig 1). Utilization of specific cardioprotective medications
Table II. Outcomes after infrainguinal lower extremity by
Outcome
Total
n  90
Perioperative N (%)
Mortality 47 (1.6
Complications
Need for reoperation 360 (12.
MI or dysrhythmia 208 (7.2
Wound infection 154 (5.3
Length of stay (days) means ( SD)/median 7.7 (7.7)/
One-year follow-upa
Mortality (%) 10.9
Major amputation (%) 9.1
Graft patency (%)
Primary 70.1
Primary-assisted 78.8
Secondary 80.9
CLI, Critical limb ischemia; IC, intermittent claudication; MI, myocardial i
aData from 2009 excluded.reveals a significant increase in the use of aspirin (P .0001), Alopidogrel (P .0001), statins (P .0001), and beta block-
rs (P .0001) among the CLI group.
Over the time period of study, there was a significant
ncrease in the proportion of LEBs performed for ICs (P
0001), with 19% in 2003, and 31% in 2009 (Fig 2). This
ncrease corresponded to increasing use of LEB for IC
mong sites that were added to the database over the
nterval of study (Fig 3).
The use of endovascular intervention prior to LEB
ncreased significantly between 2003 and 2009. Among the
C group, the rate of prior endovascular intervention in-
reased from 13% in 2003 to 23% in 2009 (P  .02).
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Fig 1. Inpatient trends in use of medical therapies.
with univariate analysis by indication
IC
n  797
CLI
n  2110 P value
N (%) N (%)
2 (0.3) 45 (2.1) .0003
43 (5.4) 317 (15.0) .0001
24 (3.0) 184 (8.7) .0001
36 (4.5) 118 (5.6) .25
4.0 (4.3)/3.0 9.2 (8.2)/
7.0
.0001
3.7 13.6 .0001
1.6 12.2 .0001
.0001
78.9 66.4
87 75.1
89 77.4
on.pass,
7
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Volume 55, Number 6 Simons et al 1633intervention has more than doubled, from 11% in 2003 to
24% in 2009 (P  .0001; Fig 4).
Trends of in-hospital outcomes by indication.
In-hospital outcomes demonstrated mixed results over the
time period studied (Fig 5). For the total cohort, there were
9 in-hospital deaths (2.3%) in 2003 compared to 7 (1.5%)
in 2009 (P  .27). In the CLI group, there were 9
in-hospital deaths (3%) in 2003, and 7 in 2009 (2%; P 
.42). The in-hospital mortality among claudicants did not
change significantly, with an extremely low event rate; there
were was either zero or one death observed in each year of
study.
There was no significant change in the rates of in-
hospital MI/dysrhythmia (9% in 2003 and 8% in 2009; P
.44; Fig 6). This holds true for the IC group (5.3% in 2003
and 2% in 2009; P .71), and the CLI group (9% in 2003
and 10% in 2009; P  .15). Among the total cohort, the
need for reoperation (defined as return to the operating
room within the index admission for infection, thrombosis,
19.1 21
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Fig 2. Annual proportion of infrainguinal lower extremity by-
passes for claudication and for critical limb ischemia, P  .001.
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Fig 3. Univariate effect of additional sites to the Vascular Study
Group of New England on annual proportion of infrainguinal
lower extremity bypasses for intermittent claudication, 2003 to
2009. In order to protect the anonymity of sites as they were
added, the analyses were performed as comparisons between year
groups to assess the effect of adding new centers over time.or revision) decreased steadily from 16% in 2003 to 6% in H009 (P  .0001). Similar decreases were seen in the two
ubgroups (Fig 5).Mean lengths of stay have also decreased
ignificantly (Fig 7); among the total cohort, mean length
f stay in 2003 was 9.8 days, which decreased to 5.8 days by
009 (P  .0001).
Trends in 1-year outcomes by indication. There was
o significant decrease in 1-year mortality among either
roup (Table III). Among the CLI cohort, mortality de-
reased from 18% in 2003 to 10% in 2008 (P .24), while
mong the IC group, mortality decreased from 3.5% to
.2% (P  .32).
Graft patency has not changed over time. There was no
ignificant change among the CLI group (secondary pa-
ency was 75% in 2003 compared to 83% in 2008; P .47);
imilarly among the IC cohort, secondary patency was 93%
n 2003 and 94% in 2008 (P  .68). Major amputation
ates also did not change over time among the IC group.
13.2
16.1
12
20.2
24.3
19
22.5
10.9
16.5 16.5
21.7
18.8
22.4
23.9
0
5
10
15
20
25
30
2003
2004
2005
2006
2007
2008
2009
2003
2004
2005
2006
2007
2008
2009
Claudication Critical Limb Ischemia
ig 4. Percentage of patients with history of endovascular
ntervention prior to infrainguinal lower extremity bypass. P for
rend .0204 for intermittent claudication, P for trend for critical
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11% in 2008 (P  .02).
One-year AFS did not demonstrate a significant change
over the time period of study (Table III). Among the CLI
group, AFS was 73% in 2003 and 81% in 2008 (P  .10).
Among the IC group, AFS was 97% in 2003 and 98% in
2008 (P  .63).
DISCUSSION
Our analysis of LEB practice patterns and outcomes at
community and academic centers in New England provides
a snapshot of in-hospital and 1-year treatment results in
contemporary, everyday vascular surgery practice. A paucity
of literature is available to provide real-world estimates of
LEB practice patterns and outcomes due primarily to issues
of sample size, selection bias, and limited clinical detail.
For example, patients with CLI and BASIL2 reported a
5.6% in-hospital mortality rate and a 68% 1-year AFS rate
among those undergoing open revascularization, and the
PREVENT III1 trial reported a 78% 1-year AFS rate.
However, these results represent a highly selected group of
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Fig 6. Trends in use of cardioprotective medications (beta block-
ers, statins, or antiplatelet agents) and in-hospital operative myo-
cardial infarction (MI)/dysrhythmia, among the total cohort. P for
trend  .0001 for cardioprotective medications, P for trend 
.4384 for MI/dysrhythmia.
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Fig 7. Inpatient trends in mean lengths of stay.patients, and include patients that were treated nearly a pecade ago. Other authors, like Nowygrod et al,6 have used
arge national administrative databases to overcome the
ias imparted by randomized controlled trials and single-
nstitution series. However, studies of this nature are often
imited by the temporal delay associated with administrative
ata availability (all patients were treated prior to 2004).6
n addition, because administrative datasets rely on dis-
harge abstractions, important patient-level clinical data are
ften lacking. Last, LaMuraglia et al7 reported outcomes of
EB using the private sector National Surgical Quality
mprovement Project. However, this dataset does not offer
ignificant clinical detail regarding specific vascular out-
omes,8 and is limited to short-term follow-up only.
In addition to describing contemporary LEB out-
omes, our study indicates that, although LEB is still more
ommonly performed for CLI, the proportion of patients
eceiving surgical bypass for IC has increased significantly.
his change correlates with the addition of new centers to
he VSGNE over the period of study. Although the exact
ause of this shift in practice patterns is unknown, several
ossible explanations exist. First, a fundamental change
ay have occurred in the approach to patients with CLI.
or example, more patients with CLI may be receiving
ndovascular intervention as an initial revascularization
trategy. If true, this more aggressive posture toward endo-
ascular therapy might have led to a decrease in the number
f patients with CLI requiring a surgical bypass.9 If the
roportion of patients with IC receiving endovascular in-
ervention instead of LEB is not increasing at the same rate
s patients with CLI, the relative proportion of patients
ith CLI undergoing LEB compared to patients with IC
ould decrease. However, in order to address this, more
nformation is needed on the outcomes of patients receiv-
ng endovascular intervention only. It would also be useful
o know the indication for prior endovascular intervention,
articularly to identify patients with CLI for whom the
ndovascular procedure was for IC but the disease subse-
uently progressed to CLI when the LEB was performed.
ccordingly, our regional quality improvement initiative
as been modified in order to begin collecting this data for
uture study.
A second possible explanation for the observed change
n practice pattern may be a shift in strategies for treating
C. Given the ready availability and minimally invasive
ature of endovascular interventions, it may be that an
ncreasing number of patients with IC are offered percuta-
eous revascularization.10 The high rates of prior endovas-
ular intervention seen among the IC group may reflect a
treatment trap”; once the decision has been made to
ntervene procedurally for IC, surgeons may feel obliged to
erform an open revascularization if a prior endovascular
pproach has not succeeded in symptom resolution. Again,
ur future regional efforts to study both open and endo-
ascular treatment strategies, and eventually even disease-
ased registries that incorporate both treated and untreated
atients with both claudication and CLI, will help to sup-
ort or refute this hypothesis.
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the use of perioperative cardioprotective medications over
time, particularly aspirin and statins. However, there has
not been a concomitant reduction in perioperative mortal-
ity or cardiac events. While the reason for this is not clear, a
plausible explanation may be that this represents a type-2
error. The small numbers of event rates, particularly on
subset analyses of either the CLI or IC group, may not
allow for detecting a difference over the time period of
study. Rather than concluding that these improvements in
compliance with medical therapy have had no impact, we
would favor re-evaluating this issue as more data becomes
available in the future.
The lack of significant improvements in long-term sur-
vival and AFS could also potentially relate to sample size,
particularly in the IC group where these event rates are very
low. However, among the CLI group, this lack of improve-
ment may underscore the severity of systemic illness asso-
ciated with CLI. In some cases, graft patency does not
correlate with limb salvage. Regardless of limb salvage,
patients with CLI are still at risk for death due to other
causes, with a particular focus on those patients at highest
risk.
Certain limitations inherent to this study design must
be acknowledged. First, our dataset is currently limited on
the specifics of the prior endovascular intervention, includ-
ing the indication, and we did not provide outcomes asso-
ciated with endovascular-alone strategies. Accordingly, we
revised our registry to capture this information for future
analyses. Second, our registry is currently procedurally
based, not disease-based. Thus, we do not have data on the
natural history of chronic lower extremity ischemia, man-
aged nonoperatively or with primary amputation. We also
have noted the effect of additional sites on the increasing
proportion of LEBs performed for claudication, but have
not pursued further analyses of the effect of these additional
centers on any of the major outcome variables. The mission
of VSGNE is for quality improvement, rather than compar-
Table III. Trends in 1-year outcomes; data from 2009 ex
Variable 2003 (%) 2004 (%) 2005 (%)
Claudication
AFS 96.5 94.4 92.7
Mortality 3.5 3.9 5.9
Major amputation 0.0 1.9 1.5
Graft patency 93.4 87.7 85.1
Primary 90.8 78.4 71.5
Primary-assisted 93.4 87.7 85.1
Secondary 93.4 87.7 85.1
CLI
AFS 72.9 76.7 74.1
Mortality 18.1 13.2 14.3
Major amputation 15.4 14.4 15.8
Graft patency 75.2 77.4 78.9
Primary 67.3 68.5 67.9
Primary-assisted 75.2 76.1 75.6
Secondary 75.2 77.4 78.9
AFS, Amputation-free survival; CLI, critical limb ischemia.isons of surgeon outcomes within the registry.In summary, among 2907 infrainguinal LEBs per-
ormed for chronic lower extremity ischemia between 2003
nd 2009 in New England, an increasing proportion was
erformed for IC, up from 19.1% in 2003 to 30.8% in
009. In addition, rates of prior endovascular interventions
ave increased in both groups while in-hospital outcomes
ave remained excellent in patients with either IC or CLI.
owever, a deeper understanding of the drivers of these
hanges in practice patterns will require more detail about
he use of endovascular interventions in our region. Ac-
ordingly, we have expanded our regional quality improve-
ent effort not only to help us understand the volume and
utcomes of open and endovascular revascularization for
C and CLI, but also how better to identify patient sub-
roups that will benefit most from each revascularization
trategy.
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